{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:58:07Z","timestamp":1791979087350,"version":"4.4.0"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2019,8,26]],"date-time":"2019-08-26T00:00:00Z","timestamp":1566777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,3,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Daptomycin is one of the few treatment options for infections caused by enterococci that are resistant to ampicillin and vancomycin, such as vancomycin-resistant Enterococcus faecium. The emergence and clinical significance of daptomycin-resistant enterococci and evolving microbiologic, pharmacokinetic-pharmacodynamic, and clinical data indicated that the pre-2019 Clinical and Laboratory Standards Institute (CLSI) susceptible-only breakpoint of \u22644 \u03bcg\/mL for daptomycin and enterococci was no longer appropriate. After analyzing data that are outlined in this article, the CLSI Subcommittee on Antimicrobial Susceptibility Testing established new breakpoints for daptomycin and enterococci. For E. faecium, a susceptible dose-dependent (SDD) breakpoint of \u22644 \u03bcg\/mL was established based on an increased dosage of 8\u201312 mg\/kg\/day (\u22658 \u03bcg\/mL-resistant). CLSI suggests infectious diseases consultation to guide daptomycin use for the SDD category. For Enterococcus faecalis and other enterococcal species, revised breakpoints of \u22642 \u03bcg\/mL-susceptible, 4 \u03bcg\/mL-intermediate, and \u22658 \u03bcg\/mL-resistant were established based on a standard dosage of 6 mg\/kg\/day.<\/jats:p>","DOI":"10.1093\/cid\/ciz845","type":"journal-article","created":{"date-parts":[[2019,8,23]],"date-time":"2019-08-23T11:44:37Z","timestamp":1566560677000},"page":"1240-1246","source":"Crossref","is-referenced-by-count":51,"title":["Development of Daptomycin Susceptibility Breakpoints for <i>Enterococcus faecium<\/i> and Revision of the Breakpoints for Other Enterococcal Species by the Clinical and Laboratory Standards Institute"],"prefix":"10.1093","volume":"70","author":[{"given":"Michael J","family":"Satlin","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, Weill Cornell Medicine , New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P","family":"Nicolau","sequence":"additional","affiliation":[{"name":"Center for Anti-Infective Research and Development, Hartford Hospital , Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romney M","family":"Humphries","sequence":"additional","affiliation":[{"name":"Accelerate Diagnostics , Tucson, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph L","family":"Kuti","sequence":"additional","affiliation":[{"name":"Center for Anti-Infective Research and Development, Hartford Hospital , Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelley A","family":"Campeau","sequence":"additional","affiliation":[{"name":"Accelerate Diagnostics , Tucson, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James S","family":"Lewis II","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Oregon Health and Science University , Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melvin P","family":"Weinstein","sequence":"additional","affiliation":[{"name":"Departments of Medicine and Pathology and Laboratory Medicine Rutgers Robert Wood Johnson Medical School , New Brunswick, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James H","family":"Jorgensen","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Texas Health Sciences Center at San Antonio"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,8,26]]},"reference":[{"key":"2024111411412346400_CIT0001","author":"US Food and Drug Administration: CUBICIN (daptomycin) Label","year":"2019"},{"key":"2024111411412346400_CIT0002","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1086\/420818","article-title":"The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections","volume":"38","author":"Arbeit","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2024111411412346400_CIT0003","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa053783","article-title":"Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus","volume":"355","author":"Fowler","year":"2006","journal-title":"N Engl J Med"},{"key":"2024111411412346400_CIT0004","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.diagmicrobio.2005.07.001","article-title":"Antimicrobial activity of daptomycin tested against clinical strains of indicated species isolated in North American medical centers (2003)","volume":"53","author":"Sader","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2024111411412346400_CIT0005","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1128\/AAC.47.11.3561-3566.2003","article-title":"Analysis of daptomycin efficacy and breakpoint standards in a murine model of Enterococcus faecalis and Enterococcus faecium renal infection","volume":"47","author":"Alder","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"2024111411412346400_CIT0006","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1055\/s-2007-996410","article-title":"Optimizing therapy for vancomycin-resistant enterococci (VRE)","volume":"28","author":"Linden","year":"2007","journal-title":"Semin Respir Crit Care Med"},{"key":"2024111411412346400_CIT0007","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/cid\/ciw113","article-title":"Causative organisms and associated antimicrobial resistance in healthcare-associated, central line-associated bloodstream infections from oncology settings, 2009\u20132012","volume":"62","author":"See","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2024111411412346400_CIT0008","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.bbmt.2010.05.008","article-title":"The changing epidemiology of vancomycin-resistant Enterococcus (VRE) bacteremia in allogeneic hematopoietic stem cell transplant (HSCT) recipients","volume":"16","author":"Kamboj","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"2024111411412346400_CIT0009","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1086\/500139","article-title":"Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer","volume":"42","author":"Jaksic","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2024111411412346400_CIT0010","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1128\/AAC.49.4.1664-1665.2005","article-title":"Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy","volume":"49","author":"Lewis","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"2024111411412346400_CIT0011","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1086\/432121","article-title":"Emergence of resistance to daptomycin during treatment of vancomycin-resistant Enterococcus faecalis infection","volume":"41","author":"Munoz-Price","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2024111411412346400_CIT0012","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1086\/659152","article-title":"Emergence of daptomycin-resistant VRE: experience of a single institution","volume":"32","author":"Kamboj","year":"2011","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2024111411412346400_CIT0013","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jinf.2016.11.004","article-title":"Daptomycin non-susceptible Enterococcus faecium in leukemia patients: role of prior daptomycin exposure","volume":"74","author":"DiPippo","year":"2017","journal-title":"J Infect"},{"key":"2024111411412346400_CIT0014","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1093\/cid\/ciw173","article-title":"Influence of minimum inhibitory concentration in clinical outcomes of Enterococcus faecium bacteremia treated with daptomycin: is it time to change the breakpoint?","volume":"62","author":"Shukla","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2024111411412346400_CIT0015","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/cid\/cix024","article-title":"Effect of daptomycin dose on the outcome of vancomycin-resistant, daptomycin-susceptible Enterococcus faecium bacteremia","volume":"64","author":"Chuang","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2024111411412346400_CIT0016","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1093\/cid\/ciw815","article-title":"Comparative effectiveness and safety of standard-, medium-, and high-dose daptomycin strategies for the treatment of vancomycin-resistant enterococcal bacteremia among Veterans Affairs patients","volume":"64","author":"Britt","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2024111411412346400_CIT0017","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1093\/cid\/ciy749","article-title":"Pharmacodynamic analysis of daptomycin-treated enterococcal bacteremia: is it time to change the breakpoint","volume":"68","author":"Avery","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2024111411412346400_CIT0018","volume-title":"Development of in vitro susceptibility testing criteria and quality control parameters","author":"Clinical and Laboratory Standards Institute","year":"2018","edition":"5th ed"},{"key":"2024111411412346400_CIT0019","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jgar.2015.04.003","article-title":"Analysis of 5-year trends in daptomycin activity tested against Staphylococcus aureus and enterococci from European and US hospitals (2009\u20132013)","volume":"3","author":"Sader","year":"2015","journal-title":"J Glob Antimicrob Resist"},{"issue":"9","key":"2024111411412346400_CIT0020","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00745-18","article-title":"Variability of daptomycin MIC values for Enterococcus faecium when measured by reference broth microdilution and gradient diffusion tests","volume":"62","author":"Campeau","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2024111411412346400_CIT0021","doi-asserted-by":"crossref","first-page":"e00600","DOI":"10.1128\/JCM.00600-19","article-title":"The new, new daptomycin breakpoint for Enterococcus spp","volume":"57","author":"Humphries","year":"2019","journal-title":"J Clin Microbiol"},{"key":"2024111411412346400_CIT0022","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/jac\/dkg337","article-title":"Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model","volume":"52","author":"Dandekar","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"2024111411412346400_CIT0023","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1128\/AAC.48.1.63-68.2004","article-title":"In vivo pharmacodynamic activity of daptomycin","volume":"48","author":"Safdar","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"2024111411412346400_CIT0024","doi-asserted-by":"crossref","first-page":"e00506","DOI":"10.1128\/AAC.00506-18","article-title":"Pharmacodynamics of daptomycin against Enterococcus faecium and Enterococcus faecalis in the murine thigh infection model","volume":"62","author":"Kidd","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2024111411412346400_CIT0025","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1128\/AAC.48.8.2799-2807.2004","article-title":"Population pharmacokinetics of daptomycin","volume":"48","author":"Dvorchik","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"2024111411412346400_CIT0026","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.clinthera.2015.04.008","article-title":"Clinical outcomes of daptomycin for vancomycin-resistant Enterococcus bacteremia","volume":"37","author":"Moise","year":"2015","journal-title":"Clin Ther"},{"key":"2024111411412346400_CIT0027","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1128\/AAC.00526-13","article-title":"Multicenter study of high-dose daptomycin for treatment of enterococcal infections","volume":"57","author":"Casapao","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2024111411412346400_CIT0028","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1016\/j.clinthera.2016.09.011","article-title":"Vancomycin-resistant enterococcal bloodstream infections in hematopoietic stem cell transplant recipients and patients with hematologic malignancies: impact of daptomycin MICs of 3 to 4 mg\/L","volume":"38","author":"Chong","year":"2016","journal-title":"Clin Ther"},{"key":"2024111411412346400_CIT0029","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1592\/phco.29.7.792","article-title":"Daptomycin therapy for vancomycin-resistant enterococcal bacteremia: a retrospective case series of 30 patients","volume":"29","author":"Gallagher","year":"2009","journal-title":"Pharmacotherapy"},{"key":"2024111411412346400_CIT0030","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jmii.2017.08.025","article-title":"Clinical characteristics and treatment outcomes of vancomycin-resistant Enterococcus faecium bacteremia","volume":"51","author":"Ye","year":"2018","journal-title":"J Microbiol Immunol Infect"},{"key":"2024111411412346400_CIT0031","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1093\/jac\/dkr255","article-title":"Vancomycin-resistant enterococcal bacteraemia and daptomycin: are higher doses necessary?","volume":"66","author":"King","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"2024111411412346400_CIT0032","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1128\/AAC.02943-14","article-title":"Impact of different antimicrobial therapies on clinical and fiscal outcomes of patients with bacteremia due to vancomycin-resistant enterococci","volume":"58","author":"Hayakawa","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2024111411412346400_CIT0033","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1097\/CCM.0000000000003264","article-title":"Survival of patients with vancomycin-resistant Enterococcus faecium bacteremia treated with conventional or high doses of daptomycin or linezolid is associated with the rate of bacterial clearance","volume":"46","author":"Chuang","year":"2018","journal-title":"Crit Care Med"},{"key":"2024111411412346400_CIT0034","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1086\/652767","article-title":"Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis","volume":"50","author":"Bhavnani","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2024111411412346400_CIT0035","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1128\/AAC.47.4.1318-1323.2003","article-title":"Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects","volume":"47","author":"Dvorchik","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"2024111411412346400_CIT0036","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1128\/AAC.00247-06","article-title":"Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers","volume":"50","author":"Benvenuto","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2024111411412346400_CIT0037","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1111\/j.1742-1241.2008.01854.x","article-title":"A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram-positive bacteria","volume":"62","author":"Katz","year":"2008","journal-title":"Int J Clin Pract"},{"key":"2024111411412346400_CIT0038","doi-asserted-by":"crossref","first-page":"5626","DOI":"10.1128\/AAC.00038-12","article-title":"Randomized controlled trial of the safety and efficacy of daptomycin versus standard-of-care therapy for management of patients with osteomyelitis associated with prosthetic devices undergoing two-stage revision arthroplasty","volume":"56","author":"Byren","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2024111411412346400_CIT0039","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12941-016-0130-8","article-title":"Real-world daptomycin use across wide geographical regions: results from a pooled analysis of CORE and EU-CORE","volume":"15","author":"Seaton","year":"2016","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"2024111411412346400_CIT0040","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1007\/s12325-015-0267-4","article-title":"Evaluation of effectiveness and safety of high-dose daptomycin: results from patients included in the European Cubicin(\u00ae) outcomes registry and experience","volume":"32","author":"Seaton","year":"2015","journal-title":"Adv Ther"},{"key":"2024111411412346400_CIT0041","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12879-016-1420-7","article-title":"Daptomycin &gt; 6 mg\/kg\/day as salvage therapy in patients with complex bone and joint infection: cohort study in a regional reference center","volume":"16","author":"Roux","year":"2016","journal-title":"BMC Infect Dis"},{"key":"2024111411412346400_CIT0042","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ijantimicag.2016.04.022","article-title":"Safety of treatment with high-dose daptomycin in 102 patients with infective endocarditis","volume":"48","author":"Durante-Mangoni","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"2024111411412346400_CIT0043","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jiac.2016.09.001","article-title":"Eosinophilic pneumonia caused by daptomycin: six cases from two institutions and a review of the literature","volume":"23","author":"Hirai","year":"2017","journal-title":"J Infect Chemother"},{"key":"2024111411412346400_CIT0044","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2024111411412346400_CIT0045","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1161\/CIR.0000000000000296","article-title":"Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of infectious complications: a scientific statement for healthcare professionals from the American Heart Association","volume":"132","author":"Baddour","year":"2015","journal-title":"Circulation"},{"key":"2024111411412346400_CIT0046","volume-title":"Performance standards for antimicrobial susceptibility testing","author":"Clinical and Laboratory Standards Institute","year":"2019","edition":"29th ed"},{"key":"2024111411412346400_CIT0047","volume-title":"Performance standards for antimicrobial susceptibility testing","author":"Clinical and Laboratory Standards Institute","year":"2019","edition":"30th ed"},{"key":"2024111411412346400_CIT0048","volume-title":"Performance standards for antifungal susceptibility testing of yeasts","author":"Clinical and Laboratory Standards Institute","year":"2017","edition":"1st ed"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciz845\/30049243\/ciz845.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/70\/6\/1240\/32756953\/ciz845.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/70\/6\/1240\/32756953\/ciz845.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T12:32:13Z","timestamp":1731587533000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/70\/6\/1240\/5554742"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,26]]},"references-count":48,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,8,26]]},"published-print":{"date-parts":[[2020,3,3]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciz845","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,3,15]]},"published":{"date-parts":[[2019,8,26]]}}}